nChroma Bio

nChroma (formerly Chroma Medicine)

The company develops programmable epigenetic editing therapies and delivery technologies for patients with chronic hepatitis B and other genetic diseases.

Bluejay Therapeutics

The company develops monoclonal antibody therapies and small molecule drugs to treat patients with chronic hepatitis B, hepatitis D and other liver diseases.

AusperBio

This biopharmaceutical company develops oligonucleotide therapies and targeted delivery platforms for patients with chronic hepatitis B and other genetic or viral diseases.

Hone Bio

This company develops lipid nanoparticle targeting technology for pharmaceutical and biotechnology firms to enable precise drug delivery beyond the liver.

Antios Therapeutics

This clinical-stage biopharmaceutical company develops antiviral therapies to treat and cure patients with chronic hepatitis B virus infections.

Spot Biosystems

This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.

Epitome Therapeutics

This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.

In vivo cell reprogramming

Enoda Bio develops genetic medicines that reprogram patient cells inside the body to treat chronic diseases for healthcare providers and pharmaceutical partners.